BEAM analyst estimates

Beam Therapeutics (BEAM) analyst ratings, the average price target and its range, and every firm's latest call.

BEAM analyst ratings and price targets

DateFirmCallTarget
Oct 29, 2026Canaccord GenuityBeam Therapeutics price target raised to $79 from $78 at Canaccord$79.00
May 21, 2026H.C. WainwrightH.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)$80.00
May 13, 2026Tudor PickeringBeam Therapeutics price target lowered to $39 from $40 at Bernstein$39.00
Feb 25, 2026RBC CapitalBeam Therapeutics price target raised to $26 from $22 at RBC Capital$26.00
Feb 20, 2026Canaccord GenuityBeam Therapeutics initiated with a Buy at Canaccord$74.00
Jan 21, 2026Tudor PickeringBeam Therapeutics Inc (BEAM) PT Raised at Bernstein Following Positive Regulatory Update$41.00
Jan 20, 2026BernsteinBeam Therapeutics price target raised to $41 from $37 at Bernstein$41.00
Jan 7, 2026UBSUBS Starts Beam Therapeutics Inc (BEAM) at Neutral$28.00
Nov 24, 2025Evercore ISIBeam Therapeutics initiated with an Outperform at Evercore ISI$35.00
Oct 9, 2025JefferiesBeam Therapeutics initiated with a Buy at Jefferies$41.00
May 7, 2025GuggenheimBeam Therapeutics price target lowered to $55 from $78 at Guggenheim$55.00
Mar 3, 2025ScotiabankBeam Therapeutics price target raised to $25 from $24 at Scotiabank$25.00
Jan 7, 2025Tudor PickeringBernstein SocGen Group Upgrades Beam Therapeutics Inc (BEAM) to Outperform$37.00
Nov 6, 2024Leerink PartnersLeerink Partners Upgrades Beam Therapeutics Inc (BEAM) to Outperform, 'we see a far more attractive risk/reward'$39.00
Nov 5, 2024BMO CapitalBMO Capital on Beam Therapeutics Inc (BEAM): 'We see BEAM-101 clinical data as positive'$57.00

Updated 2026-11-03 00:00 UTC